These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38765003)

  • 21. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
    Shalabi H; Harrison C; Yates B; Calvo KR; Lee DW; Shah NN
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30741. PubMed ID: 37897136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
    Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
    Front Immunol; 2022; 13():877477. PubMed ID: 35464403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
    Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
    Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
    Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
    Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
    Front Immunol; 2022; 13():965224. PubMed ID: 36059496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.
    Berger SC; Fehse B; Akyüz N; Geffken M; Wolschke C; Janson D; Gagelmann N; Luther M; Wichmann D; Frenzel C; Thayssen G; Alegiani A; Badbaran A; Zeschke S; Dierlamm J; Kröger N; Ayuk FA
    Haematologica; 2023 Feb; 108(2):444-456. PubMed ID: 35950534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients.
    Gust J; Rawlings-Rhea SD; Wilson AL; Tulberg NM; Sherman AL; Seidel KD; Wu QV; Park JR; Gardner RA; Annesley CE
    Blood Adv; 2023 Mar; 7(6):1001-1010. PubMed ID: 36006611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
    Tan AP
    Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature.
    Alsdorf WH; Schmitz M; Schieferdecker A; Dierlamm J; Bokemeyer C; Binder M
    J Oncol Pharm Pract; 2016 Jun; 22(3):523-7. PubMed ID: 25655468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
    Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
    J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
    Kersten MJ; van Ettekoven CN; Heijink DM
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
    Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
    Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy.
    Tang JP; Peters CW; Quiros C; Wang X; Klomhaus AM; Yamada RE; Timmerman JM; Moore TB; Nowicki TS
    Cancer Immunol Res; 2022 Dec; 10(12):1433-1440. PubMed ID: 36259217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
    Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.